Clinical Trials
11
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
- Conditions
- TraumaAdult Stem Cells
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Healios K.K.
- Target Recruit Count
- 156
- Registration Number
- NCT04533464
- Locations
- 🇺🇸
Healios Investigational Site, Houston, Texas, United States
MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)
- Conditions
- ARDS
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Healios K.K.
- Target Recruit Count
- 400
- Registration Number
- NCT04367077
- Locations
- 🇺🇸
Athersys Investigational Site 107, Chicago, Illinois, United States
🇺🇸Athersys Investigational Site 103, Akron, Ohio, United States
🇺🇸Athersys Investigational Site 101, Cleveland, Ohio, United States
Efficacy and Safety Study of HLCM051(MultiStem®) for Pneumonic Acute Respiratory Distress Syndrome
- Conditions
- Respiratory Distress Syndrome, Adult
- First Posted Date
- 2019-01-17
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Healios K.K.
- Target Recruit Count
- 35
- Registration Number
- NCT03807804
- Locations
- 🇯🇵
Investigational Site Number 027, Nagoya, Aichi, Japan
🇯🇵Investigational Site Number 028, Nagoya, Aichi, Japan
🇯🇵Investigational Site Number 005, Seto, Aichi, Japan
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study
- Conditions
- Ischemic Stroke
- First Posted Date
- 2018-06-04
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Healios K.K.
- Target Recruit Count
- 300
- Registration Number
- NCT03545607
- Locations
- 🇺🇸
Athersys Investigational Site 128, Phoenix, Arizona, United States
🇺🇸Athersys Investigational Site 122, Palo Alto, California, United States
🇺🇸Athersys Investigational Site 127, Sacramento, California, United States
Treatment Evaluation of Acute Stroke for Using in Regenerative Cell Elements
- Conditions
- Stroke, Acute
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Healios K.K.
- Target Recruit Count
- 206
- Registration Number
- NCT02961504
- Locations
- 🇯🇵
Hokkaido University Hospital, Sapporo, Japan
- Prev
- 1
- 2
- 3
- Next
News
Acute Ischemic Stroke Pipeline Shows Promise with 25+ Therapies in Development and Recent Clinical Breakthroughs
DelveInsight's 2025 analysis reveals over 20 key companies are developing 25+ acute ischemic stroke therapies across various clinical phases, representing significant advancement in stroke treatment research.